vs

Side-by-side financial comparison of Columbia Financial, Inc. (CLBK) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $68.8M, roughly 1.2× Columbia Financial, Inc.). Columbia Financial, Inc. runs the higher net margin — 22.8% vs -38.1%, a 60.9% gap on every dollar of revenue. On growth, Columbia Financial, Inc. posted the faster year-over-year revenue change (29.7% vs 20.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 17.7%).

Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota. It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

CLBK vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.2× larger
PRCT
$83.1M
$68.8M
CLBK
Growing faster (revenue YoY)
CLBK
CLBK
+9.5% gap
CLBK
29.7%
20.2%
PRCT
Higher net margin
CLBK
CLBK
60.9% more per $
CLBK
22.8%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
17.7%
CLBK

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CLBK
CLBK
PRCT
PRCT
Revenue
$68.8M
$83.1M
Net Profit
$15.7M
$-31.6M
Gross Margin
64.9%
Operating Margin
28.6%
-4.1%
Net Margin
22.8%
-38.1%
Revenue YoY
29.7%
20.2%
Net Profit YoY
173.9%
-27.9%
EPS (diluted)
$0.15
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBK
CLBK
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$68.8M
$76.4M
Q3 25
$67.3M
$83.3M
Q2 25
$63.9M
$79.2M
Q1 25
$58.8M
$69.2M
Q4 24
$46.4M
$68.2M
Q3 24
$54.3M
$58.4M
Q2 24
$53.3M
$53.4M
Net Profit
CLBK
CLBK
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$15.7M
$-29.8M
Q3 25
$14.9M
$-21.4M
Q2 25
$12.3M
$-19.6M
Q1 25
$8.9M
$-24.7M
Q4 24
$-21.2M
$-18.9M
Q3 24
$6.2M
$-21.0M
Q2 24
$4.5M
$-25.6M
Gross Margin
CLBK
CLBK
PRCT
PRCT
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
CLBK
CLBK
PRCT
PRCT
Q1 26
-4.1%
Q4 25
28.6%
-40.6%
Q3 25
29.5%
-27.8%
Q2 25
25.8%
-28.0%
Q1 25
20.4%
-39.7%
Q4 24
-57.6%
-28.9%
Q3 24
13.5%
-38.4%
Q2 24
9.0%
-50.3%
Net Margin
CLBK
CLBK
PRCT
PRCT
Q1 26
-38.1%
Q4 25
22.8%
-39.1%
Q3 25
22.1%
-25.7%
Q2 25
19.3%
-24.7%
Q1 25
15.1%
-35.8%
Q4 24
-45.7%
-27.6%
Q3 24
11.4%
-35.9%
Q2 24
8.5%
-48.0%
EPS (diluted)
CLBK
CLBK
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.15
$-0.54
Q3 25
$0.15
$-0.38
Q2 25
$0.12
$-0.35
Q1 25
$0.09
$-0.45
Q4 24
$-0.20
$-0.34
Q3 24
$0.06
$-0.40
Q2 24
$0.04
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBK
CLBK
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$340.8M
$245.6M
Total DebtLower is stronger
$1.2B
$51.7M
Stockholders' EquityBook value
$1.2B
$347.7M
Total Assets
$11.0B
$487.1M
Debt / EquityLower = less leverage
1.02×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBK
CLBK
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$340.8M
$286.5M
Q3 25
$253.4M
$294.3M
Q2 25
$248.2M
$302.7M
Q1 25
$256.1M
$316.2M
Q4 24
$289.2M
$333.7M
Q3 24
$283.5M
$196.8M
Q2 24
$391.1M
$214.1M
Total Debt
CLBK
CLBK
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$1.2B
$51.6M
Q3 25
$1.3B
$51.6M
Q2 25
$1.3B
$51.5M
Q1 25
$1.1B
$51.5M
Q4 24
$1.1B
$51.5M
Q3 24
$1.4B
$51.4M
Q2 24
$1.7B
$51.4M
Stockholders' Equity
CLBK
CLBK
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$1.2B
$365.9M
Q3 25
$1.1B
$380.3M
Q2 25
$1.1B
$385.8M
Q1 25
$1.1B
$389.2M
Q4 24
$1.1B
$402.2M
Q3 24
$1.1B
$241.2M
Q2 24
$1.0B
$251.8M
Total Assets
CLBK
CLBK
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$11.0B
$508.1M
Q3 25
$10.9B
$511.5M
Q2 25
$10.7B
$513.1M
Q1 25
$10.6B
$519.4M
Q4 24
$10.5B
$534.0M
Q3 24
$10.7B
$374.1M
Q2 24
$10.8B
$374.4M
Debt / Equity
CLBK
CLBK
PRCT
PRCT
Q1 26
0.15×
Q4 25
1.02×
0.14×
Q3 25
1.11×
0.14×
Q2 25
1.14×
0.13×
Q1 25
1.01×
0.13×
Q4 24
1.00×
0.13×
Q3 24
1.32×
0.21×
Q2 24
1.61×
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBK
CLBK
PRCT
PRCT
Operating Cash FlowLast quarter
$68.4M
Free Cash FlowOCF − Capex
$58.6M
FCF MarginFCF / Revenue
85.1%
Capex IntensityCapex / Revenue
14.3%
Cash ConversionOCF / Net Profit
4.36×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBK
CLBK
PRCT
PRCT
Q1 26
Q4 25
$68.4M
$-10.3M
Q3 25
$31.0M
$-6.6M
Q2 25
$14.6M
$-15.0M
Q1 25
$-1.6M
$-17.0M
Q4 24
$33.3M
$-32.4M
Q3 24
$-28.3M
$-18.8M
Q2 24
$18.6M
$-15.7M
Free Cash Flow
CLBK
CLBK
PRCT
PRCT
Q1 26
Q4 25
$58.6M
$-12.2M
Q3 25
$28.1M
$-9.5M
Q2 25
$12.9M
$-17.8M
Q1 25
$-4.5M
$-18.8M
Q4 24
$25.9M
$-33.6M
Q3 24
$-31.1M
$-19.0M
Q2 24
$17.2M
$-16.8M
FCF Margin
CLBK
CLBK
PRCT
PRCT
Q1 26
Q4 25
85.1%
-15.9%
Q3 25
41.8%
-11.4%
Q2 25
20.2%
-22.5%
Q1 25
-7.6%
-27.2%
Q4 24
55.7%
-49.2%
Q3 24
-57.3%
-32.6%
Q2 24
32.3%
-31.4%
Capex Intensity
CLBK
CLBK
PRCT
PRCT
Q1 26
Q4 25
14.3%
2.4%
Q3 25
4.2%
3.4%
Q2 25
2.7%
3.5%
Q1 25
4.9%
2.7%
Q4 24
16.0%
1.7%
Q3 24
5.1%
0.4%
Q2 24
2.6%
2.0%
Cash Conversion
CLBK
CLBK
PRCT
PRCT
Q1 26
Q4 25
4.36×
Q3 25
2.08×
Q2 25
1.19×
Q1 25
-0.18×
Q4 24
Q3 24
-4.57×
Q2 24
4.09×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLBK
CLBK

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons